Families who suspect autism can wait up to two years for an evaluation. Dr. Latha Valluripalli Soorya, a clinical psychologist at Rush University Medical Center and co-founder of Argus Cognitive, and Dr. Erica Crawford, Clinical Director at Autism Testing 4 Kids in Dallas–Fort Worth, join Steve Labkoff and Leon Rozenblit to discuss Neurora: smart glasses a clinician wears during a standard autism assessment, with software that measures a child's gaze, facial movement and speech. AT4K was a reimbursed site in its FDA study. They cover what the clinician gets back, the hard cases where the data helps, what the published study does and doesn't show, and why the biggest time savings so far came from report writing.

Ninety-five percent of drug targets fail, and Professor Sir Peter Donnelly thinks the reason is simple: we can't run experiments on humans. Genetics is the next best thing. People who carry natural variants in a gene show what happens when that gene is dialed up or down over a lifetime. Peter, CEO and co-founder of Genomics, joins Steve Labkoff and Leon Rozenblit to explain how his company harmonized tens of thousands of genetic studies into one resource, what genetics revealed about "good" cholesterol, why the AI agent sits on top rather than at the core, and what genetics still can't tell a drug developer.

Doctors hallucinate too. That's the provocation Travis Zack, MD, PhD, chief medical officer of OpenEvidence, brings to this conversation with Steve Labkoff and Leon Rozenblit. A physician with 20 patients and no time to look things up goes with their gut, and can get it wrong in the same ways a language model does. Travis explains why OpenEvidence was built on retrieving evidence rather than generating answers, what makes one set of references better than another, how it grades the strength of evidence behind an answer in real time, why health systems and EHR vendors act as gatekeepers, and why the last mile of a clinical decision still belongs to a human.